Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Can Meta-Analysis Save Vertebroplasty?

Can Meta-Analysis Save Vertebroplasty? Last February, I was asked to testify in front of the California Technology Assessment Forum (CTAF), a public service forum composed of numerous California physicians and health experts who assess new and emerging medical technology, on behalf of DePuy Spine regarding vertebroplasty as a treatment for osteoporotic compression fractures. The review was prompted by the publication of 2 randomized controlled trials in the New England Journal of Medicine ( NEJM ), 1 , 2 which questioned the efficacy of vertebroplasty. Blue Shield of California Foundation spearheads the CTAF, managing the technology assessment reviews and organizing all CTAF meetings and events. Because my flight was delayed by the thick slow-rolling fog, which blankets San Francisco during that time of year, I was able to arrive just a few moments before the start of the session. I was on a panel of 5 physicians, each of whom was given 5 minutes to talk. Dr Leah Karliner, Assistant Professor of Medicine at the University of California, San Francisco, opened the talks by discussing that on the basis of the NEJM articles, vertebroplasty does not meet the CTAF criteria 3–5 for safety, effectiveness, and improvement in health outcomes for the treatment of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Neuroradiology American Journal of Neuroradiology

Can Meta-Analysis Save Vertebroplasty?

Georgy, B.
American Journal of Neuroradiology , Volume 32 (4): 614 – Apr 1, 2011
Download PDF
3 pages

Loading next page...
 
/lp/american-journal-of-neuroradiology/can-meta-analysis-save-vertebroplasty-y0DGA9dZYB
Publisher
American Journal of Neuroradiology
Copyright
Copyright © 2011 by the American Society of Neuroradiology.
ISSN
0195-6108
eISSN
1936-959X
DOI
10.3174/ajnr.A2377
Publisher site
See Article on Publisher Site

Abstract

Last February, I was asked to testify in front of the California Technology Assessment Forum (CTAF), a public service forum composed of numerous California physicians and health experts who assess new and emerging medical technology, on behalf of DePuy Spine regarding vertebroplasty as a treatment for osteoporotic compression fractures. The review was prompted by the publication of 2 randomized controlled trials in the New England Journal of Medicine ( NEJM ), 1 , 2 which questioned the efficacy of vertebroplasty. Blue Shield of California Foundation spearheads the CTAF, managing the technology assessment reviews and organizing all CTAF meetings and events. Because my flight was delayed by the thick slow-rolling fog, which blankets San Francisco during that time of year, I was able to arrive just a few moments before the start of the session. I was on a panel of 5 physicians, each of whom was given 5 minutes to talk. Dr Leah Karliner, Assistant Professor of Medicine at the University of California, San Francisco, opened the talks by discussing that on the basis of the NEJM articles, vertebroplasty does not meet the CTAF criteria 3–5 for safety, effectiveness, and improvement in health outcomes for the treatment of

Journal

American Journal of Neuroradiology – American Journal of Neuroradiology

Published: Apr 1, 2011

There are no references for this article.